FDA-cleared profile

RevealAI-Lung

Precision Medical Ventures, Inc. Dba Revealdx · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Characterization and relative cancer-risk assessment of incidentally detected pulmonary nodules 6-15 mm in adults, with use as one input to follow-up and clinical decision-making under published guidelines; not lung-cancer screening

Clinical role
User-selected CADx adjunct during routine lung CT interpretation: the radiologist identifies the nodule, opens an integrated MIMPS frame, and considers mSI with other risk factors and guidelines
Images and patients
CT/CTA · Pulmonary nodules in the lungs
Key limitation
Keep in mind: Not indicated for lung-cancer screening, modalities other than lung CT, non-lung-nodule locations, or unassisted reads; intended indication is adult incidentally detected nodules 6-15 mm; missing CT slices were excluded from validation

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Characterization and relative cancer-risk assessment of incidentally detected pulmonary nodules 6-15 mm in adults, with use as one input to follow-up and clinical decision-making under published guidelines; not lung-cancer screening
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Pulmonary nodules in the lungs Input: DICOM CT image plus a spatial coordinate centered on a user-selected lung nodule; incidentally detected 6-15 mm pulmonary nodule in a patient aged 18 years or above; validation excluded CT images with missing slices
  • Who uses it?Intended users: Radiologists; the packet states RevealAI-Lung is intended only for radiologists and requires practitioner review
  • What does the software produce?Output: Malignancy similarity index (mSI) from 0 to 1 for each selected nodule, plus a histogram relating the score to benign and malignant NLST reference cases; mSI is a relative risk score and not a percentage cancer risk
  • What is its most important limitation?Key limitation: Not indicated for lung-cancer screening, modalities other than lung CT, non-lung-nodule locations, or unassisted reads; intended indication is adult incidentally detected nodules 6-15 mm; missing CT slices were excluded from validation

Clinical takeaway. Clinical role: Characterization and relative cancer-risk assessment of incidentally detected pulmonary nodules 6-15 mm in adults, with use as one input to follow-up and clinical decision-making under published guidelines; not lung-cancer screening

Evidence takeaway. Evidence from the reviewed source record: FDA packet reports validation on 675 patients, including 276 with cancer, across additional US, Canadian, and UK populations. The MRMC study used 108 cases and 10 radiologists with a 28-day washout. Primary endpoint was reader AUC: mean 0.538 unaided versus 0.719 aided, delta 0.181, p<0.0001. At a prespecified 5% malignancy-likelihood threshold, reader sensitivity changed from 0.68 to 0.82 and specificity from 0.344 to 0.467; the packet cautions these are sample-dependent and not population statistics

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Characterization and relative cancer-risk assessment of incidentally detected pulmonary nodules 6-15 mm in adults, with use as one input to follow-up and clinical decision-making under published guidelines; not lung-cancer screening
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
User-selected CADx adjunct during routine lung CT interpretation: the radiologist identifies the nodule, opens an integrated MIMPS frame, and considers mSI with other risk factors and guidelines
  • Exact FDA submission
  • Checked 2026-09-08
Required input
DICOM CT image plus a spatial coordinate centered on a user-selected lung nodule; incidentally detected 6-15 mm pulmonary nodule in a patient aged 18 years or above; validation excluded CT images with missing slices
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Malignancy similarity index (mSI) from 0 to 1 for each selected nodule, plus a histogram relating the score to benign and malignant NLST reference cases; mSI is a relative risk score and not a percentage cancer risk
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Hospitals and healthcare provider office settings
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Radiologists; the packet states RevealAI-Lung is intended only for radiologists and requires practitioner review
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Not indicated for lung-cancer screening, modalities other than lung CT, non-lung-nodule locations, or unassisted reads; intended indication is adult incidentally detected nodules 6-15 mm; missing CT slices were excluded from validation
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA packet reports validation on 675 patients, including 276 with cancer, across additional US, Canadian, and UK populations. The MRMC study used 108 cases and 10 radiologists with a 28-day washout. Primary endpoint was reader AUC: mean 0.538 unaided versus 0.719 aided, delta 0.181, p<0.0001. At a prespecified 5% malignancy-likelihood threshold, reader sensitivity changed from 0.68 to 0.82 and specificity from 0.344 to 0.467; the packet cautions these are sample-dependent and not population statistics
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA packet reports validation on 675 patients, including 276 with cancer, across additional US, Canadian, and UK populations. The MRMC study used 108 cases and 10 radiologists with a 28-day washout. Primary endpoint was reader AUC: mean 0.538 unaided versus 0.719 aided, delta 0.181, p<0.0001. At a prespecified 5% malignancy-likelihood threshold, reader sensitivity changed from 0.68 to 0.82 and specificity from 0.344 to 0.467; the packet cautions these are sample-dependent and not population statistics
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

RevealAI-Lung regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K251769
  • Samplen=675
  • IndependenceIndependence not established

K251769

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K251769. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM CT image plus a spatial coordinate centered on a user-selected lung nodule; incidentally detected 6-15 mm pulmonary nodule in a patient aged 18 years or above; validation excluded CT images with missing slices

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K251769: RevealAI-Lung

  2. Routing

    Source context, not route validation: Imports DICOM from connected third-party devices, interfaces with an established MIMPS system, and displays analytics in an integrated frame; the packet says it does not display DICOM images and does not provide reporting-archive connectivity. Specific PACS/RIS interfaces and versions are not established

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K251769: RevealAI-Lung

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 ·

  4. Returned objects

    Source context, not route validation: Malignancy similarity index (mSI) from 0 to 1 for each selected nodule, plus a histogram relating the score to benign and malignant NLST reference cases; mSI is a relative risk score and not a percentage cancer risk

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K251769: RevealAI-Lung

  5. Viewer/worklist/report

    Unresolved route: Malignancy similarity index (mSI) from 0 to 1 for each selected nodule, plus a histogram relating the score to benign and malignant NLST reference cases; mSI is a relative risk score and not a percentage cancer risk

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K251769: RevealAI-Lung

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Imports DICOM from connected third-party devices, interfaces with an established MIMPS system, and displays analytics in an integrated frame; the packet says it does not display DICOM images and does not provide reporting-archive connectivity. Specific PACS/RIS interfaces and versions are not established
  • Exact FDA submission
  • Checked 2026-09-08

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for RevealAI-Lung; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251769
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Pulmonary nodules in the lungs
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-01-30
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
21Fields reviewed
9Source classes checked
2Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision summary, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K251769 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-08 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K251769: RevealAI-Lung

    U.S. Food and Drug Administration - Published 2026-01-30 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. RevealAI-Lung model card (K251769)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K251769

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K251769 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K254075

Synapse Lung Nodule AI

Fujifilm Corporation

Authorized purpose: Concurrent-reader aid for a radiologist detecting pulmonary nodules during review of chest CT examinations in the lung cancer screening population under screening protocols.

Modality
CT/CTA
Anatomy
Chest/lungs; pulmonary nodules
Decision
2026-05-27
FDA-cleared K251474

Median LCS (internal name) / eyonis LCS (trade name) (1.0)

Median Technologies

eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2026-02-06

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history